# Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

> **NCT02052388** · PHASE2 · COMPLETED · sponsor: **Cellceutix Corporation** · enrollment: 215 (actual)

## Conditions studied

- Skin Infection
- Bacterial Infection

## Interventions

- **DRUG:** Daptomycin
- **DRUG:** Brilacidin

## Key facts

- **NCT ID:** NCT02052388
- **Lead sponsor:** Cellceutix Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2018-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052388, "Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02052388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*